General
Preferred name
levamisole
Synonyms
LEVAMISOLE HYDROCHLORIDE ()
(-)-Tetramisole hydrochloride ()
Levamisole HCl ()
Levamisole (hydrochloride) ()
Levamisole HCl ()
TETRAMIZOLE HYDROCHLORIDE ()
(-)-Tetramisole ()
R 12,564 ()
NSC-177023 ()
R-12564 ()
Levamisoli hydrochloridum ()
Ascaridil ()
R 12654 ()
Ergamisol ()
Solaskil ()
L-narpenol ()
Ketrax ()
Tetramisole hydrochloride, (s)- ()
Spartakon l ()
Tetramisole, (s)- ()
TCMDC-125847 ()
(?)-Levamisole (hydrochloride) (CRM) ()
(?)-Levamisole ()
P&D ID
PD009109
CAS
16595-80-5
14769-73-4
Tags
natural product
drug
available
Approved by
FDA
First approval
1990
Drug Status
investigational
withdrawn
approved
vet_approved
Drug indication
Parasitic infection
Colon cancer
Biological Response Modifier
Max Phase
Phase 4
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Levamisole is the levorotatory isomer of tetramisole (PubChem CID 3913). This drug was originally used to treat intestinal worm infestations, but also found use in cancer treatment due to its antineoplastic action. This drug is not currently in clinical use in the US or Canada. (GtoPdb)
INDICATION For adjuvant treatment in combination with fluorouracil after surgical resection in patients with Dukes' stage C colon cancer. Also used to treat malignant melanoma and head/neck cancer.
DESCRIPTION Inhibits multiple mammalian alkaline phosphatases (LOPAC library)
DESCRIPTION Levamisole, a thiazole derivative, has been found to be an antibiotic used to against parasitic worm infections and could also have potential activity in anticancer study. (BOC Sciences Bioactive Compounds)
Cell lines
0
Organisms
2
Compound Sets
25
Axon Medchem Screening Library
3242
BOC Sciences Bioactive Compounds
levamisole-cas-14769-73-4-item-59162
Cayman Chemical Bioactives
14874
21321
33972
CeMM library of unique drugs (CLOUD)
ChEMBL Approved Drugs
CHEMBL1770
CHEMBL1454
ChEMBL Drugs
CHEMBL1770
CHEMBL1454
Drug Repurposing Hub
DrugBank
DB00848
DrugBank Approved Drugs
DB00848
DrugCentral
1561
DrugCentral Approved Drugs
1561
DrugMAP
DM5EN79
DrugMAP Approved Drugs
DM5EN79
Enamine BioReference Compounds
Guide to Pharmacology
7210
LOPAC library
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL1454
Mcule NIBR MoA Box Subset
MCULE-4392506462
MedChem Express Bioactive Compound Library
HY-13666
HY-A0106
Novartis Chemogenetic Library (NIBR MoA Box)
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
Levamisole-Hydrochloride(Ergamisol)
TargetMol Bioactive Compound Library
T0944
Withdrawn 2.0
w51
External IDs
59
Properties
(calculated by RDKit )
Molecular Weight
204.07
Hydrogen Bond Acceptors
3
Hydrogen Bond Donors
0
Rotatable Bonds
1
Ring Count
3
Aromatic Ring Count
1
cLogP
2.15
TPSA
15.6
Fraction CSP3
0.36
Chiral centers
1.0
Largest ring
6.0
QED
0.7
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
MOA
helminthic nicotinic acetylcholine receptor agonist
Nicotinic Receptor Agonists
immunostimulant
acetylcholine receptor agonist
Target
Nicotinic acetylcholine receptor alpha subunit
nAChR
PLAP
ALPPL2, CHRNA3
ALPL
Anthelmintic agent
HSV
Parasite
Immunology & Inflammation related
Pathway
Metabolism
Neuroscience
Anti-infection
Membrane Transporter/Ion Channel
Neuronal Signaling
Member status
member
Indication
gastrointestinal parasites
ATC
P02CE01
Toxicity type
hematological
Therapeutic Class
Anticancer Agents
Source data